Brain Tumors

ADVL1312: A Phase I/II Study of MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

Principal Investigator: Katherine Matthay, MD

 

ADVL1414: A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors

Principal Investigator: Katherine Matthay, MD

 

ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Principal Investigator: Katherine Matthay, MD

 

ACNS1022: A Phase II Randomized Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytoma and Optic Pathway Gliomas

Principal Investigator: Anuradha Banerjee, MD, MPH

 

ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

Principal Investigator: Anuradha Banerjee, MD, MPH

 

ACNS1221: A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age

Principal Investigator: Sabine Mueller, MD, PhD

 

GSK Trametinib: An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects with Cancer or Plexiform Neurofibromas and Trametinib in Combination with Dabrafenib in Children and Adolescents with Cancers Harboring V600 mutation

Principal Investigator: Sabine Mueller, MD, PhD

 

PBTC-029: A Phase I and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Principal Investigator: Anuradha Banerjee, MD

 

PNOC-001: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children

Principal Investigator: Sabine Mueller, MD, PhD

 

PNOC-002: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children with Recurrent/Refractory BRAFV600E-mutant gliomas

Principal Investigator: Theodore Nicolaides, MD

 

PNOC-003: A Pilot Trial Testing the Clinical Benefits of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)

Principal Investigator: Sabine Mueller, MD, PhD

 

EZH102: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Principal Investigator: Kieuhoa Vo, MD, MAS

 

Ignyta Entrectinib: A Phase 1/1b. Open-Label, Dose-Escalation and Expannsion Study of Entrctinib in Children and Adolescents with Recurrent/Refactory Solid Tumors and Primary CNS Tumor

Principal Investigator: Amit Sabnis, MD